Apremilast for moderate-to-severe psoriasis
Part of Skin clinical trials.
This study tests a medicine called apremilast (brand name ApoLla) to see how well it works and how safe it is for people with moderate to severe psoriasis. If you have had psoriasis for 6 months or more and have not taken apremilast before, you may be a fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older
- You have had moderate to severe psoriasis for at least 6 months
- You have not taken the study drug (apremilast) before
- You do not have severe kidney disease that requires dialysis
- You agree to use effective birth control during the study if you or your partner could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cream form of the drug apremilast for mild plaque psoriasis that covers no more than 10% of your body. It aims to see if the cream is safe and works well for treating small patches of psoriasis.
This study compares two oral medications—methotrexate and apremilast—to see which works better for relieving itching in people with psoriasis. If you have psoriasis and bothersome itching, you may be able to join.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.